Fulvestrant formulations
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 61/068,560, filed Mar 7, 2008. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,801,892 | Fulvestrant Formulations In force · High confidence | Eagle Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,363,259 | Fulvestrant Formulations In force · High confidence | Eagle Pharmaceuticals, Inc. | In force | High confidence | ||
| US 9,180,088 | Fulvestrant formulations In force · High confidence | Eagle Pharmaceuticals, Inc. | In force | High confidence | ||
| Application 16/508,741 | Fulvestrant Formulations Abandoned Abandoned Sep 22, 2020 | Eagle Pharmaceuticals, Inc. | Abandoned | Abandoned Sep 22, 2020 | ||
| Application 17/022,574 | Fulvestrant Formulations Abandoned Abandoned Sep 24, 2022 | Eagle Pharmaceuticals, Inc. | Abandoned | Abandoned Sep 24, 2022 | ||
| Application 17/819,726 | Fulvestrant Formulations Abandoned Abandoned Nov 17, 2023 | Eagle Pharmaceuticals, Inc. | Abandoned | Abandoned Nov 17, 2023 | ||
| Application 18/506,633 | Fulvestrant Formulations Abandoned Abandoned Dec 11, 2024 | Eagle Pharmaceuticals, Inc. | Abandoned | Abandoned Dec 11, 2024 |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Eagle Pharmaceuticals, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.